Earlier today, as expected the Federal Circuit denied AMRN's Petition for panel rehearing and en banc review. See the attached ORDER of the court.
Get a 20-yr experienced U.S. biotech patent attorney's view of what this means for the current litigation and whether AMRN has any options left in its attempts to use its patents to stop generic Vascepa launch. Plus get monthly updates on AMRN's patents and its patent strategies to stop a generic launch. Sign up for our Patent Investor subscription today. CLICK HERE https://www.ampbioresearch.com/plans-pricing